newswire, breaking biotechnology and pharma news

Wednesday, July 18, 2012

Pharma and Biotech Stock Trading Alert; Supernus (NASDAQ:SUPN) Trades up over 17%

New York, New York - July 18, 2012 ( Newswire), an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Supernus Pharmaceuticals, Inc. (NasdaqGM :SUPN) trading up at $12.58, gaining $1.89 or 17.68% 10:35AM EDT on 176,000 shares . The stock is the morning leader on NASDAQ percentage gainers.
The most recent news from the Company was Friday, when it provided an update on the launch of its two epilepsy products; Trokendi XR(TM) and SPN-804. Newswire Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system, or CNS, diseases. The company is developing several product candidates in neurology and psychiatry to address large market opportunities in epilepsy and ADHD including ADHD patients with impulsive aggression. These product candidates include Trokendi XR (extended-release topiramate), formerly known as SPN-538, and SPN-804 (extended-release oxcarbazepine) for epilepsy, SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.

About is a leader in investor stock research by sector. Sectors we cover include; water and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, natural gas stocks, tech (includes cloud and social networking), defense stocks, nanotech,   China  stocks and agriculture.
Follow on Twitter!/Investorideas
Follow on Facebook
Sign up for the free investor news and stock alerts
Research biotech stocks at the Biotech stocks Directory:
Become an Member
Follow on Twitter!/Investorideas
Follow on Facebook a href="">
Disclaimer/ Disclosure : The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:
800-665-0411 - Source -

No comments:

Post a Comment